SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
作者信息
Siegel Corey A, Melmed Gil Y, McGovern Dermot Pb, Rai Victoria, Krammer Florian, Rubin David T, Abreu Maria T, Dubinsky Marla C
机构信息
Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
F Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA.
出版信息
Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.炎症性肠病患者的新型冠状病毒2型疫苗接种：一项国际共识会议的建议
Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.
2
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].[成人炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明]
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
3
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.炎症性肠病患者的 SARS-CoV-2 疫苗接种：英国胃肠病学会炎症性肠病分会和 IBD 临床研究小组立场声明。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8. Epub 2021 Jan 26.
4
Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients.儿童炎症性肠病患者感染或接种SARS-CoV-2后的血清转化
Inflamm Bowel Dis. 2021 Oct 20;27(11):1862-1864. doi: 10.1093/ibd/izab194.
5
Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.炎症性肠病患者感染 SARS-CoV-2 及对 COVID-19 疫苗免疫应答的风险：当前证据。
Front Immunol. 2022 Jun 23;13:933774. doi: 10.3389/fimmu.2022.933774. eCollection 2022.
6
SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.SARS-CoV-2 疫苗接种在炎症性肠病中的应用：过去的经验教训、当前的证据和未来的挑战。
J Crohns Colitis. 2021 Aug 2;15(8):1376-1386. doi: 10.1093/ecco-jcc/jjab046.
7
Ensuring High and Equitable COVID-19 Vaccine Uptake Among Patients With IBD.确保 IBD 患者的 COVID-19 疫苗高接种率和公平性。
Inflamm Bowel Dis. 2021 Oct 18;27(10):1703-1705. doi: 10.1093/ibd/izab114.
8
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease.COVID-19 疫苗接种对炎症性肠病患者的长期有效性和持久性。
Clin Gastroenterol Hepatol. 2024 Jul;22(7):1475-1486.e4. doi: 10.1016/j.cgh.2024.02.001. Epub 2024 Feb 17.
9
Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?免疫抑制治疗的炎症性肠病患者接种 SARS-CoV-2 疫苗后的体液免疫原性：我们是否应该优先考虑额外加强注射？
Inflamm Bowel Dis. 2023 Feb 1;29(2):268-273. doi: 10.1093/ibd/izac187.
10
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.英夫利昔单抗与 IBD 患者对 BNT162b2 和 ChAdOx1 nCoV-19 SARS-CoV-2 疫苗的免疫原性降低有关。
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.
引用本文的文献
1
A case of ulcerative colitis in a patient undergoing surgery due to exacerbation resulting in toxic megacolon after SARS-CoV-2 vaccination.1例溃疡性结肠炎患者在接种新型冠状病毒疫苗后病情加重，因毒性巨结肠接受手术。
Clin J Gastroenterol. 2025 Apr 28. doi: 10.1007/s12328-025-02136-9.
2
COVID-19 vaccine updates for people under different conditions.不同人群的 COVID-19 疫苗更新信息。
Sci China Life Sci. 2024 Nov;67(11):2323-2343. doi: 10.1007/s11427-024-2643-1. Epub 2024 Jul 29.
3
SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.炎症性肠病（IBD）患者的新型冠状病毒2型（SARS-CoV-2）疫苗接种——IBD治疗是否会对SARS-CoV-2抗体产生负面影响？一项单中心前瞻性研究。
Prz Gastroenterol. 2024;19(2):198-205. doi: 10.5114/pg.2023.130126. Epub 2023 Jul 27.
4
The impact of the COVID-19 pandemic on the mental health of patients diagnosed with inflammatory bowel diseases.COVID-19 大流行对炎症性肠病患者心理健康的影响。
J Med Life. 2023 Dec;16(12):1864-1868. doi: 10.25122/jml-2023-0475.
5
Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.COVID-19 治疗对炎症性肠病真实世界结局的影响。
Dig Dis Sci. 2024 May;69(5):1654-1660. doi: 10.1007/s10620-024-08355-3. Epub 2024 Mar 11.
6
Racial and ethnic differences in the degree of participation and retention in a decentralized cohort study of COVID-19 immunization in patients with inflammatory bowel diseases.炎症性肠病患者COVID-19免疫接种分散队列研究中参与度和留存率的种族和民族差异。
J Clin Transl Sci. 2024 Jan 18;8(1):e31. doi: 10.1017/cts.2024.5. eCollection 2024.
7
SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study.炎症性肠病患者接种 SARS-CoV-2 疫苗与疾病活动无关：一项瑞士单中心回顾性研究。
Ann Med. 2024 Dec;56(1):2295979. doi: 10.1080/07853890.2023.2295979. Epub 2024 Jan 30.
8
Exploring the Impact of COVID-19 on Ulcerative Colitis Patients: A Lifestyle Perspective.从生活方式角度探讨新冠病毒病对溃疡性结肠炎患者的影响
Medicina (Kaunas). 2024 Jan 20;60(1):182. doi: 10.3390/medicina60010182.
9
Crohn's disease and clinical management today: How it does?当今的克罗恩病与临床管理：现状如何？
World J Methodol. 2023 Dec 20;13(5):399-413. doi: 10.5662/wjm.v13.i5.399.
10
The change of healthcare service in Chinese patients with inflammatory bowel disease during the pandemic: a national multicenter cross-sectional study.疫情期间中国炎症性肠病患者医疗服务的变化：一项全国多中心横断面研究。
Sci Rep. 2023 Nov 16;13(1):20084. doi: 10.1038/s41598-023-46892-5.
本文引用的文献
1
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.炎症性肠病患者感染冠状病毒病的风险和结局：系统评价和荟萃分析。
United European Gastroenterol J. 2021 Mar;9(2):159-176. doi: 10.1177/2050640620972602. Epub 2021 Mar 23.
4
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
5
Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic.寒冬将至！2019冠状病毒病大流行期间炎症性肠病患者疫苗接种的临床、免疫学及实际考量
Gastroenterology. 2021 Feb;160(3):639-644. doi: 10.1053/j.gastro.2020.10.013. Epub 2020 Oct 14.
6
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
7
Fairly Prioritizing Groups for Access to COVID-19 Vaccines.合理确定获得新冠疫苗的优先群体
JAMA. 2020 Oct 27;324(16):1601-1602. doi: 10.1001/jama.2020.18513.
8
Immunological considerations for COVID-19 vaccine strategies.针对 COVID-19 疫苗策略的免疫学考虑。
Nat Rev Immunol. 2020 Oct;20(10):615-632. doi: 10.1038/s41577-020-00434-6. Epub 2020 Sep 4.
9
High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab.接受优特克单抗治疗的克罗恩病患者对流感疫苗的高免疫原性。
Vaccines (Basel). 2020 Aug 14;8(3):455. doi: 10.3390/vaccines8030455.
10
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.对患有 2019 年冠状病毒病的炎症性肠病患者的系统评价：是时候进行总结了。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2689-2700. doi: 10.1016/j.cgh.2020.08.003. Epub 2020 Aug 7.
Zotero 插件